Merck Stock Price May Hide Hidden Value, Analysts Say

Merck's stock has seen significant growth over the past five years, increasing by 101.7%. The current price of $130.20 puts it in a different place than where long-term holders started.

The company's progress on products such as alimatravir and KEYTRUDA supports cash flow expectations, but competition from generics and new therapies may pressure future pricing power.

Merck's valuation picture is mixed, with the Discounted Cash Flow (DCF) model estimating an intrinsic value of $228 per share. This represents a 43% discount to the current price, suggesting undervaluation on this measure.

The P/E ratio for Merck sits at around 36x, which is higher than both the wider industry average and closer large cap peers. However, the fair P/E ratio estimate is close to the current multiple, indicating that the stock may be priced roughly in line with what's considered fair.